Rochester, NY, Jan. 28, 2010 – ACM Global Central Laboratory, a global central lab, has launched an enhanced version of its proprietary LabStar system, which captures all clinical trial testing data in a single location for easy access and comprehensive reporting. The upgraded system is now completely compliant with the CDISC Laboratory Model, which saves considerable time and effort by standardizing the data capture format. In addition, LabStar features an auto convert function that allows users to toggle between conventional and standard interface (SI) units of report formats as required.
The Web-based platform is available on a global basis. Access is fully secure and compliant with FDA regulations, requiring proper login information for authorized individuals. Users can schedule automatic reports and receive alerts in their email when the reports are accessible. Per-subject reports are available for trial investigators and per-study reports offer sponsor analysis on enrollment status, test result trending and summary data, among many other variables. Furthermore, LabStar’s robust ad hoc reporting enables users to analyze data by any result, demographic or therapeutic detail.
“Serving our customers and providing state of the art solutions is always ACM’s priority; so much so that we formed a customer advisory committee. We value their input and strive to provide optimal solutions,” said Elena Logan, VP of Clinical Trials, ACM Global Central Lab. “We are excited to offer our clients a much more flexible, highly intuitive solution that allows them access to their lab data.”
LabStar is a value-added service that empowers users to achieve optimum protocol efficiency. Closing managing and monitoring a protocol can save time and money by making decisions with real-time results. LabStar data is in strict accordance with GCP and HIPPA regulations and now enables convenient feedback to ACM for training requests, technical issues or suggestions for continual improvement.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Zenocutuzumab Shows Durable Efficacy in NRG1 Fusion-Positive Cancers in Phase II eNRGy Trial
February 13th 2025The Phase II eNRGy trial showed durable antitumor activity with zenocutuzumab (Bizengri) in patients with NRG1 fusion–positive cancers, particularly non-small cell lung cancer and pancreatic cancer.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.